Platform for Transducing Target Cells with a Viral Vector
Application
System for quickly and efficiently obtaining therapeutic levels of transduction.
Key Benefits
- Uses less viral vector to achieve high gene transfer.
- Shortens transduction time.
- Produces clinically relevant gene modified cell numbers.
Market Summary
Information relay at the molecular level, such as the transcription of RNA into proteins, is an essential process. It is challenging to impart this type of complex dynamic behavior at a synthetic molecular level. DNA self-assembly is the current approach, however the current systems typically exhibit simple dynamic behaviors that involve, at most, only a few transformations.
Technical Summary
Emory researchers have developed a more efficient system to quickly and efficiently achieve therapeutic levels of cells transduced with viral vectors containing the desired gene therapy. This microfluidic platform can be scaled up, using a modular approach, to accommodate clinically relevant numbers of cells (≥1x109). This scalable microfluidic platform uses less viral vector, reduces transduction times, and synergizes with commercially available transduction enhancing compounds.
Developmental Stage
Publication: Tran, R. et al. (2017). Molecular Therapy, 25(10), 2372-82.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
| Nationalized PCT - United States |
United States |
17/603,266 |
|
10/12/2021 |
|
Pending |
|
|
